Jazz Pharmaceuticals enrolls first patient in leukemia treatment trial


Jazz Pharmaceuticals announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze administered intravenously as an alternative method of administration to treat patients with acute lymphoblastic leukemia with hypersensitivity to E. coli-derived asparaginase therapy. The trial is designed to enroll up to 25 acute lymphoblastic leukemia patients in the U.S. and Canada who have a documented Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli asparaginase and have not completed their full courses of prescribed asparaginase therapy. Preliminary pharmacokinetic data from the trial are expected in 2H13.

View Comments (0)